Log ud

Strålebehandling af hæmatologiske sygdomme

Kliniske retningslinjer

Dansk Lymfom Gruppe (DLG)

Dansk Lymfom Gruppe (DLG) (– Lymphoma % : Lymphoma) blev etableret i 2003 som en multidisciplinær cancergruppe med ansvar for guidelines og nationale kliniske studier omhandlende patienter med hæmatologiske sygdomme. 

DLG er ansvarlige for udarbejdelse af kliniske retningslinjer (Lymfom – DMCG – Danske Multidisciplinære Cancer Grupper)i samarbejde med DALROG (Danish Lymphoma Radiation Oncology Group), der varetager strålebehandling af hæmatologiske sygdomme. 

 

Strålebehandlingen gives i henhold til følgende ILROG guidelines:

 

  1. Specht L, Yahalom J, Illidge T, Berthelsen AK, Constine LS, Eich HT, Girinsky T, Hoppe RT, Mauch P, Mikhaeel NG, Ng A, on behalf of ILROG. Modern radiation therapy for Hodgkin lymphoma: field and dose guidelines from the International Lymphoma Radiation Oncology Group (ILROG). Int J Radiat Oncol Biol Phys 2014; 89: 854-62.  

  

  1. Illidge T, Specht L, Yahalom J, Aleman B, Berthelsen AK, Constine L, Dabaja B, Dharmar K, Ng A, Ricardi U, Wirth A. Modern radiotherapy for nodal non Hodgkin lymphoma – field and dose guidelines from the International Lymphoma Radiation Oncology Group (ILROG). Int J Radiat Oncol Biol Phys 2014; 89: 49-58.    

                                                                             

  1. Yahalom J, Illidge T, Specht L, Hoppe RT, Li Y-X, Tsang R, Wirth A, on behalf of ILROG. Modern radiotherapy for extra-nodal lymphoma – field and dose guidelines from the International Lymphoma Radiation Oncology Group (ILROG). Int J Radiat Oncol Biol Phys 2015; 92: 11-31.

 

  1. Specht L, Dabaja B, Illidge T, Wilson LD, Hoppe RT, on behalf of ILROG. Modern radiotherapy for primary cutaneous lymphomas – field and dose guidelines from the International Lymphoma Radiation Oncology Group (ILROG). Int J Radiat Oncol Biol Phys 2015; 92: 32-9.

 

  1. Ng AK, Yahalom J, Goda JS, Constine LS, Pinnix CC, Kelsey CR, Hoppe B, Oguchi M, Suh C-O, Wirth A, Qi S, Davies A, Moskowitz CH, Laskar S, Li Y, Mauch PM, Specht L, Illidge T. The role of radiation therapy in patients with relapsed/refractory diffuse large B-cell lymphoma: Guidelines from the International Lymphoma Radiation Oncology Group. Int J Radiat Oncol Biol Phys 2018; 100: 652-69. 

 

  1. Constine LS, Yahalom J, Ng A, Hodgson D, Wirth A, Milgrom S, Mikhaeel G, Eich H, Illidge T, Ricardi U, Dieckmann K, Moskowitz C, Advani R, Mauch P, Specht L, Hoppe R. The role of radiation therapy in patients with relapsed/refractory Hodgkin lymphoma: Guidelines from the International Lymphoma Radiation Oncology Group. Int J Radiat Oncol Biol Phys 2018; 100: 1100-18.

 

  1. Tsang RW, Campbell BA, Goda JS, Kelsey CR, Kirova YM, Parikh RR, Ng AK, Ricardi U, Suh C-O, Mauch PM, Specht L, Yahalom J. Radiation therapy for solitary plasmacytoma and multiple myeloma: Guidelines from the International Lymphoma Radiation Oncology Group. Int J Radiat Oncol Biol Phys 2018; 101: 794–808.

 

  1. Wong JYC, Filippi AR, Dabaja BS, Yahalom J, Specht L. Total body irradiation: Guidelines from the International Lymphoma Radiation Oncology Group (ILROG). Int J Radiat Oncol Biol Phys 2018; 101: 521-9. 

 

  1. Pinnix CC, Yahalom J, Specht L, Dabaja BS. Radiation in central nervous system leukemia: Guidelines from the International Lymphoma Radiation Oncology Group. Int J Radiat Oncol Biol Phys 2018; 102: 53-8.

 

  1. Bakst RL, Dabaja BS, Specht LK, Yahalom J. Use of radiation in extramedullary leukemia/chloroma: guidelines from the International Lymphoma Radiation Oncology Group. Int J Radiat Oncol Biol Phys 2018; 102: 314-9.

 

  1. Dabaja B, Specht L, Yahalom J. Lymphoblastic lymphoma: Guidelines from the International Lymphoma Radiation Oncology Group (ILROG). Int J Radiat Oncol Biol Phys 2018; 102: 508-14. 

 

  1. Dabaja BS, Hoppe BS, Plastaras JP, Newhauser W, Rosolova K, Flampouri S, Mohan R, Mikhaeel NG, Kirova Y, Specht L, Yahalom J. Proton therapy for adults with mediastinal lymphomas: the International Lymphoma Radiation Oncology Group guidelines. Blood 2018; 132: 1635-46.

 

  1. Mikhaeel NG, Milgrom SA, Terezakis S, Berthelsen AK, Hodgson D, Eich HT, Dieckmann K, Qi S, Yahalom J. Specht L. The optimal use of imaging in radiation therapy for lymphoma – Guidelines from the International Lymphoma Radiation Oncology Group (ILROG). Int J Radiat Oncol Biol Phys 2019; 104: 501-12.

 

  1. Dabaja BS, Ng AK, Terezakis SA, Plastaras JP, Yunes M, Wilson LD, Specht L, Yahalom J. Making every single Gray count: involved site radiation therapy delineation guidelines for hematological malignancies. Int J Radiat Oncol Biol Phys 2020; 106: 279-81.

 

  1. Dabaja BS, Ng A, Terezakis SA, Plastaras JP, Yunes M, Wilson LD, Specht L, Yahalom J. ILROG lymphoma mini-atlas. Int J Radiat Oncol Biol Phys https://doi.org/10.1016/j.ijrobp.2019.10.029

 

  1. Yahalom J, Dabaja BS, Ricardi U, Ng A, Mikhaeel NG, Vogelius IR, Illidge T, Qi S, Wirth A, Specht L. ILROG emergency guidelines for radiation therapy of hematological malignancies during the COVID-19 pandemic. Blood 2020; 135: 1829-32. 

 

  1. Wirth A, Mikhaeel NG, Aleman BMP, Pinnix CC, Constine LS, Ricardi U, Illidge TM, Eich HT, Hoppe BS, Dabaja B, Ng AK, Kirova Y, Berthelsen ‎AK, Dieckmann K, Yahalom J, Specht L. Involved Site Radiation Therapy in adult lymphomas: An Overview of International Lymphoma Radiation Oncology Group Guidelines. Int J Radiat Oncol Biol Phys 2020; 107: 909-33. 

 

  1. Dabaja BS, Ng AK, Terezakis SA, Plastaras JP, Yunes M, Wilson LD, Yang J, Gunther JR, Specht L, Yahalom J. ILROG lymphoma mini-atlas part II, Hodgkin lymphoma. Int J Radiat Oncol Biol Phys 2020; 108: 977-8.

 

  1. Qi S, Li Y, Specht L, Oguchi M, Tsang R, Ng A, Suh C, Ricardi U, Mac Manus M, Dabaja B, Yahalom J, on behalf of the International Lymphoma Radiation Oncology Group (ILROG). Modern radiation therapy for extranodal NK/T-cell lymphoma, nasal type: Risk-adapted therapy, target volume definition and dose guidelines from the International Lymphoma Radiation Oncology Group. Int J Radiat Oncol Biol Phys 2021; 110: 1064-81.